Market Closed -
OTC Markets
08:39:57 31/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.012
USD
|
-84.00%
|
|
-.--%
|
+20.00%
|
Fiscal Period: June |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
36.17
|
112
|
50.16
|
39.49
|
78.43
|
-
|
-
|
Enterprise Value (EV)
1 |
36.17
|
106.3
|
31.15
|
28.52
|
69.51
|
61.01
|
59.92
|
P/E ratio
|
-
|
-13.1
x
|
-
|
-3.47
x
|
-5.55
x
|
-2.21
x
|
-3.09
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
46.9
x
|
176
x
|
27.7
x
|
20.1
x
|
21.8
x
|
14.8
x
|
22.4
x
|
EV / Revenue
|
46.9
x
|
167
x
|
17.2
x
|
14.5
x
|
19.3
x
|
11.5
x
|
17.1
x
|
EV / EBITDA
|
-
|
-13.4
x
|
-5.46
x
|
-2.53
x
|
-5.28
x
|
-1.95
x
|
-2.56
x
|
EV / FCF
|
-
|
-1,81,95,824
x
|
-39,89,429
x
|
-34,86,569
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
19.5
x
|
2.37
x
|
3.96
x
|
5.17
x
|
2.43
x
|
4.55
x
|
Nbr of stocks (in thousands)
|
4,88,785
|
5,74,476
|
6,68,794
|
6,69,315
|
9,01,545
|
-
|
-
|
Reference price
2 |
0.0740
|
0.1950
|
0.0750
|
0.0590
|
0.0870
|
0.0870
|
0.0870
|
Announcement Date
|
26/08/20
|
25/08/21
|
31/08/22
|
25/08/23
|
-
|
-
|
-
|
Fiscal Period: June |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.7716
|
0.6368
|
1.812
|
1.965
|
3.6
|
5.3
|
3.5
|
EBITDA
1 |
-
|
-7.947
|
-5.711
|
-11.28
|
-13.17
|
-31.29
|
-23.45
|
EBIT
1 |
-
|
-8.05
|
-5.8
|
-11.37
|
-13.27
|
-31.34
|
-23.5
|
Operating Margin
|
-
|
-1,264.04%
|
-320.07%
|
-578.78%
|
-368.53%
|
-591.38%
|
-671.43%
|
Earnings before Tax (EBT)
1 |
-
|
-8.061
|
-
|
-11.38
|
-17.2
|
-14.6
|
-14.4
|
Net income
1 |
-
|
-8.061
|
-
|
-11.38
|
-13.08
|
-31.1
|
-23.27
|
Net margin
|
-
|
-1,265.72%
|
-
|
-579.19%
|
-363.2%
|
-586.79%
|
-664.85%
|
EPS
2 |
-
|
-0.0149
|
-
|
-0.0170
|
-0.0157
|
-0.0394
|
-0.0282
|
Free Cash Flow
|
-
|
-5.843
|
-7.809
|
-8.181
|
-
|
-
|
-
|
FCF margin
|
-
|
-917.42%
|
-430.95%
|
-416.37%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/08/20
|
25/08/21
|
31/08/22
|
25/08/23
|
-
|
-
|
-
|
Fiscal Period: June |
2021 S2
|
2024 S1
|
---|
Net sales
1 |
-
|
1.2
|
EBITDA
1 |
-6.01
|
-4.693
|
EBIT
1 |
-6.01
|
-4.741
|
Operating Margin
|
-
|
-395.02%
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
1 |
-
|
-4.743
|
Net margin
|
-
|
-395.24%
|
EPS
2 |
-
|
-0.006600
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
25/08/21
|
28/02/24
|
Fiscal Period: June |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
5.71
|
19
|
11
|
8.92
|
17.4
|
18.5
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-5.84
|
-7.81
|
-8.18
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-157%
|
-43.3%
|
-
|
-
|
-
|
-0.83%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-39.5%
|
-
|
-
|
-
|
-73.5%
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
31.66
|
Book Value Per Share
2 |
-
|
0.0100
|
0.0300
|
0.0100
|
0.0200
|
0.0400
|
0.0200
|
Cash Flow per Share
2 |
-
|
-0.0100
|
-0.0100
|
-0.0100
|
-0.0200
|
-0.0400
|
-0.0300
|
Capex
1 |
-
|
0.01
|
0
|
0.03
|
0.1
|
-
|
-
|
Capex / Sales
|
-
|
1.31%
|
0.22%
|
1.49%
|
2.78%
|
-
|
-
|
Announcement Date
|
26/08/20
|
25/08/21
|
31/08/22
|
25/08/23
|
-
|
-
|
-
|
Last Close Price
0.087
AUD Average target price
0.25
AUD Spread / Average Target +187.36% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.19% | 121B | | +19.91% | 114B | | +8.24% | 23.61B | | -19.80% | 20.43B | | -16.19% | 16.55B | | -13.45% | 16.45B | | -44.35% | 15.59B | | +66.67% | 15.19B | | +2.13% | 13.54B |
Bio Therapeutic Drugs
|